Cardiomegaly
|
0.500 |
Biomarker
|
phenotype |
CTD_human |
Peroxisome proliferator-activated receptor {delta} is an essential transcriptional regulator for mitochondrial protection and biogenesis in adult heart.
|
20075336 |
2010 |
Cardiomegaly
|
0.500 |
Biomarker
|
phenotype |
RGD |
Nuclear factor-kappaB activation leads to down-regulation of fatty acid oxidation during cardiac hypertrophy.
|
15728586 |
2005 |
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
Complementary Immunometabolic Effects of Exercise and PPARβ/δ Agonist in the Context of Diet-Induced Weight Loss in Obese Female Mice.
|
31635041 |
2019 |
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
Previous investigations have shown that the peroxisome proliferator activated receptor beta/delta (PPAR<beta>/<delta>)-angiopoietin-like protein 4 (ANGPTL4) pathways may be a new pharmacologic target for treatment of obesity.
|
28320596 |
2019 |
Obesity
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The nuclear hormone receptor peroxisome proliferator-activated receptor delta (PPARδ) is a ligand-dependent transcription factor involved in fatty acid metabolism, obesity, wound healing, inflammation, and cancer.
|
31239272 |
2019 |
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
PPARβ/δ activation might help prevent the development of metabolic disorders, including obesity, dyslipidaemia, type 2 diabetes mellitus and non-alcoholic fatty liver disease.
|
29558390 |
2018 |
Obesity
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Regarding new generation drugs, acting on both α/γ, β/δ, or α/δ receptors simultaneously, preliminary data on PPAR-α/γ dual agonists revealed a positive effect on lipid profile, blood pressure, atherosclerosis, inflammation, and anti-coagulant effects, while the overexpression of PPAR-β/δ seems to prevent obesity and to decrease lipid storage in cardiac cells.
|
28098353 |
2018 |
Obesity
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
These results suggest that G. frondosa is a novel functional food that may prevent life-style related diseases like obesity and diabetes, and that these beneficial effects are likely to be mediated through the activation of PPARδ and a PPARδ-independent insulin signaling pathway.
|
29873587 |
2018 |
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
Using mice with an intestinal epithelial cell-specific deletion of PPARδ, we show that intestinal PPARδ protects against diet-induced obesity, insulin resistance and dyslipidemia.
|
28404991 |
2017 |
Obesity
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Accumulated evidence suggests that the polymorphism rs2016520 in PPARD is associated with lipid metabolism, obesity, metabolic syndrome, and type 2 diabetes mellitus.
|
28128413 |
2017 |
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
We aimed at investigating the influence of obesity on sirtuins' levels, their role in obesity-associated inflammation, and the relationship with the peroxisome proliferator-activated receptor delta, which also plays functions in adipose tissue metabolism.
|
27844208 |
2017 |
Obesity
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
To investigate the association of haplotypes of PPAR δ gene rs2016520 and rs9794 with abnormal weight (BMI ≥ 24 kg/m(2)) and abdominal obesity (WC ≥ 90 cm for males and ≥ 80 cm for females) in a Chinese Han population.
|
26073637 |
2016 |
Obesity
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Polymorphism of rs2016520 in gene PPARD has been associated with lipid metabolism, obesity, metabolic syndrome and type 2 diabetes mellitus (T2DM).
|
26915488 |
2016 |
Obesity
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This study aimed to investigate the association of peroxisome proliferator-activated receptor (PPAR) genes PPARα L162V, PPARγ2 C161T and PPARδ T294C single nucleotide polymorphisms (SNPs) with obesity and metabolic syndrome (Met-S) in a multi-ethnic population in Kampar, Malaysia.
|
26673968 |
2015 |
Obesity
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our population and ethnic-based study demonstrates that the PPARδ +294C allele maybe an independent risk of IS in Chinese Uyghurs especially in the male (OR 1.99, 95%CI:1.06-3.72) and obesity populations (OR 2.36, 95%CI: 1.19-4.67), which were consistent with Tunisian Population.
|
26346611 |
2015 |
Obesity
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Peroxisome proliferator-activated receptor-β/δ (PPARδ) is a ubiquitously expressed, ligand-activated transcriptional factor that performs diverse critical functions in normal cells (e.g., fatty acid metabolism, obesity, apoptosis, and inflammation).
|
23041232 |
2013 |
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
Gene-gene interaction between PPARδ and PPARγ is associated with abdominal obesity in a Chinese population.
|
23273766 |
2012 |
Obesity
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Telmisartan prevents weight gain and obesity through activation of peroxisome proliferator-activated receptor-delta-dependent pathways.
|
20176998 |
2010 |
Obesity
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Previous studies have identified a single-nucleotide polymorphism in the gene encoding peroxisome proliferator-activated receptor-delta (PPARD), rs2016520, that is associated with changes in metabolic disease in some but not all studies, which suggests that PPARD agonists may have therapeutic benefits for the treatment of metabolic disorders, including dyslipidemia, type 2 diabetes, and obesity.
|
20200337 |
2010 |
Obesity
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Genetic association studies of single-nucleotide polymorphisms in the PPARD gene have only provided negative or conflicting evidence for gross phenotypes such as obesity, hyperlipidaemia and type 2 diabetes.
|
19512923 |
2009 |
Obesity
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In addition, we have found a significant interaction between CAPN5 and PPARD genes (p = 0.038) that reduces the risk for obesity in a 55%.
|
18657264 |
2008 |
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our study reveals a novel mechanism by which PPARdelta regulates lipogenesis, suggesting potential therapeutic applications of PPARdelta modulators in obesity and type 2 diabetes, as well as related steatotic liver diseases.
|
18627005 |
2008 |
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
Moreover, PPARdelta augments physical endurance and increases oxidative metabolism, thereby averting obesity.
|
17431579 |
2007 |
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
Peroxisome proliferator-activated receptor-delta (PPARdelta) is a nuclear receptor implicated in lipid oxidation and the pathogenesis of obesity and diabetes.
|
16966336 |
2006 |
Obesity
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons.
|
16168052 |
2005 |